share_log

Capital Investment Advisors LLC Has $3.79 Million Stock Position in Danimer Scientific, Inc. (NYSE:DNMR)

Financial News Live ·  Sep 16, 2022 10:22

Capital Investment Advisors LLC grew its stake in Danimer Scientific, Inc. (NYSE:DNMR – Get Rating) by 0.4% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 830,998 shares of the company's stock after purchasing an additional 3,000 shares during the quarter. Capital Investment Advisors LLC owned about 0.82% of Danimer Scientific worth $3,789,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in DNMR. Northern Trust Corp increased its position in shares of Danimer Scientific by 33.5% in the 4th quarter. Northern Trust Corp now owns 868,043 shares of the company's stock valued at $7,396,000 after buying an additional 217,881 shares in the last quarter. ProShare Advisors LLC bought a new stake in shares of Danimer Scientific in the 4th quarter valued at $169,000. Raymond James & Associates increased its position in shares of Danimer Scientific by 18.4% in the 4th quarter. Raymond James & Associates now owns 55,958 shares of the company's stock valued at $477,000 after buying an additional 8,693 shares in the last quarter. Bank of America Corp DE increased its position in shares of Danimer Scientific by 63.7% in the 4th quarter. Bank of America Corp DE now owns 390,724 shares of the company's stock valued at $3,329,000 after buying an additional 152,056 shares in the last quarter. Finally, AlphaCrest Capital Management LLC bought a new stake in shares of Danimer Scientific in the 4th quarter valued at $343,000. Institutional investors and hedge funds own 44.98% of the company's stock.

Get Danimer Scientific alerts:

Insider Transactions at Danimer Scientific

In other news, CMO Scott Tuten sold 10,000 shares of the firm's stock in a transaction that occurred on Monday, July 18th. The shares were sold at an average price of $5.08, for a total transaction of $50,800.00. Following the completion of the transaction, the chief marketing officer now directly owns 474,136 shares of the company's stock, valued at approximately $2,408,610.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, Director Stuart W. Pratt sold 75,327 shares of the firm's stock in a transaction on Thursday, August 18th. The shares were sold at an average price of $5.25, for a total value of $395,466.75. Following the completion of the transaction, the director now directly owns 1,519,238 shares of the company's stock, valued at $7,975,999.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CMO Scott Tuten sold 10,000 shares of the firm's stock in a transaction on Monday, July 18th. The shares were sold at an average price of $5.08, for a total transaction of $50,800.00. Following the completion of the transaction, the chief marketing officer now directly owns 474,136 shares of the company's stock, valued at $2,408,610.88. The disclosure for this sale can be found here. Insiders sold 95,327 shares of company stock valued at $496,867 in the last ninety days. 14.60% of the stock is currently owned by corporate insiders.

Danimer Scientific Price Performance

Shares of DNMR opened at $3.91 on Friday. The stock has a market capitalization of $393.93 million, a P/E ratio of -6.52 and a beta of 1.08. Danimer Scientific, Inc. has a twelve month low of $3.09 and a twelve month high of $20.40. The company has a 50 day moving average of $4.66 and a 200-day moving average of $4.67. The company has a quick ratio of 5.53, a current ratio of 6.60 and a debt-to-equity ratio of 0.56.

Danimer Scientific (NYSE:DNMR – Get Rating) last issued its quarterly earnings results on Tuesday, August 9th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.04). The business had revenue of $12.70 million for the quarter. Danimer Scientific had a negative return on equity of 19.28% and a negative net margin of 104.97%. As a group, equities research analysts forecast that Danimer Scientific, Inc. will post -0.82 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, Cowen lowered their target price on Danimer Scientific to $6.00 in a report on Monday, August 15th.

About Danimer Scientific

(Get Rating)

Danimer Scientific, Inc, a performance polymer company, develops, produces, and provides bioplastic replacements for traditional petroleum-based plastics. It produces polyhydroxyalkanoate, a biodegradable plastic feedstock alternative used in a range of plastic applications, including films, straws, food containers, and other things under the Nodax brand name; polylactic acid-based resins for coating disposable paper cups; and other biopolymers.

Further Reading

  • Get a free copy of the StockNews.com research report on Danimer Scientific (DNMR)
  • Is There a Cure for What is Ailing Teladoc Stock?
  • No One Told These 3 Stocks It's a Down Week
  • Why Medical Products Maker Repligen May Be A Potential Buy
  • At 10%, Is Arbor Realty Trust Dividend Worth It?
  • Investors Should Tune Into RF Industries

Want to see what other hedge funds are holding DNMR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danimer Scientific, Inc. (NYSE:DNMR – Get Rating).

Receive News & Ratings for Danimer Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danimer Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment